Skip to main content
Go to homepage

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Description:

For complete information, please view the study on clinicaltrials.gov.

This study is being done in collaboration with Cincinnati Children's Hospital.

Study Status:
Closed
Full IRB Study Title:
ADVL1513: A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
IRB Study ID:
1042403-1
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research, Stem Cell Transplantation & Shannon E. Wilkes Targeted Therapy Program; The Jeffrey A. Barbour Chair for Pediatric Hematology Oncology Research and Healing; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program